Top Tweets for #Prostatecancers
Congratulations to @WCMEnglanderIPM's Clinical Director Dr. Cora Sternberg (@cnsternberg) on her new paper in the @OncJournal, "Molecular Landscape of #ProstateCancers with #ClivalMetastases."
https://t.co/9bYrx0o4y0
Aggressive variant #ProstateCancers. Presentation by @aaparicioMD @MDAndersonNews. #ESMO25 written coverage by @zklaassen_md @GACancerCenter > https://t.co/fSjNv79xv8 @myESMO
Histopathologic features and transcriptomic signatures do not solve the issue of magnetic resonance imaging-invisible #ProstateCancers: a matched-pair analysis. #ProstateCancer invisibility on mpMRI ≠ indolence! A matched-pair study found no histopathologic or transcriptomic differences explaining MRI-invisible tumors—some still show aggressive features. #ReadNow > https://t.co/72KsSy5sLa @oderdam
Histopathologic features and transcriptomic signatures do not solve the issue of magnetic resonance imaging-invisible #ProstateCancers: a matched-pair analysis. #ProstateCancer invisibility on mpMRI ≠ indolence! A matched-pair study found no histopathologic or transcriptomic differences explaining MRI-invisible tumors—some still show aggressive features. #ReadNow > https://t.co/72KsSy5sLa @oderdam
Histopathologic features and transcriptomic signatures do not solve the issue of magnetic resonance imaging-invisible #ProstateCancers: a matched-pair analysis. #ProstateCancer invisibility on mpMRI ≠ indolence! A matched-pair study found no histopathologic or transcriptomic differences explaining MRI-invisible tumors—some still show aggressive features. #ReadNow > https://t.co/72KsSy5sLa @oderdam
Histopathologic features and transcriptomic signatures do not solve the issue of magnetic resonance imaging-invisible #ProstateCancers: a matched-pair analysis. #ProstateCancer invisibility on mpMRI ≠ indolence! A matched-pair study found no histopathologic or transcriptomic differences explaining MRI-invisible tumors—some still show aggressive features. #ReadNow > https://t.co/72KsSy5sLa @oderdam
Histopathologic features and transcriptomic signatures do not solve the issue of magnetic resonance imaging-invisible #ProstateCancers: a matched-pair analysis. #ProstateCancer invisibility on mpMRI ≠ indolence! A matched-pair study found no histopathologic or transcriptomic differences explaining MRI-invisible tumors—some still show aggressive features. #ReadNow > https://t.co/72KsSy5sLa @oderdam
New research from MSK supported the approval of a new treatment for ER-positive, #HER2-negative advanced #breastcancer; suggests a new strategy for overcoming resistance to Akt inhibitors in patients with PTEN-mutated #prostatecancers; provides new understanding of B cell #lymphomas that could lead to new treatments; examines using #ChatGPT to help capture patient-reported outcomes; and more: https://t.co/2pR6hWF3Uj
Interesting paper! #LynchSyndrome carriers with MSH2 & MSH6 mutations at significant risk of developing aggressive #prostatecancers.
Many tumors do NOT show loss of MMR proteins and are MSS. So should universal germline testing be offered to all patients to determine LS status?
Outcomes of 10 years of PSA screening for prostate cancer in Norwegian men with Lynch syndrome
https://t.co/5fAI99qNHP
This prospective observational study investigated #ProstateCancer (PCa) incidence and characteristics in 225 male carriers of pathogenic germline variants in mismatch repair (MMR) genes, specifically focusing on the MSH2 and MSH6 genes, who underwent annual PSA screening in Norway. Of the participants, 22 (9.8%) developed PCa, with MSH2 and MSH6 carriers showing the highest incidence rates (14.5% and 13.1%, respectively). Half of the tumors had a Gleason score ≥4+3, indicating aggressive disease, and a substantial proportion had advanced pathological stages. The standardized incidence ratio (SIR) for all MMR carriers was 9.54, with even higher SIRs for MSH2 (13.0) and MSH6 (13.74) carriers, suggesting a significantly increased PCa risk.
These findings support the continuation of PSA screening for MSH2 and MSH6 carriers, though further studies are needed to refine screening recommendations for other MMR gene carriers.
@ManuelaZucknick
ping
@Silke_Gillessen
@AOmlin
@OncoAlert
@bavilima
@nataliagandur
Our colleagues, Drs. Brian Robinson and Chair Massimo Loda participated in an expert panel (image) last fall on metastatic castrate-resistant and neuroendocrine and #ProstateCancers. The resulting Clinical Cancer Research paper was just published.
https://t.co/zWBqV63pZC
Natural killer cell infiltration in #ProstateCancers predicts improved patient outcomes. Nicholas Zorko, MD, PhD @UMNews joins @AndreaMiyahira @PCFnews to discuss the promising role of NK cells described in his team's work published in @pcan_journal > https://t.co/CVQdQVJpQ7
Cancer researchers at @cityofhope demonstrated promising clinical activity in CAR T-cell therapy for certain #braincancers and #prostatecancers in two new groundbreaking studies. Read the summaries here: https://t.co/v9NEHrS07J
Natural killer cell infiltration in #ProstateCancers predicts improved patient outcomes. Nicholas Zorko, MD, PhD @UMNews joins @AndreaMiyahira @PCFnews to discuss the promising role of NK cells described in his team's work published in @pcan_journal > https://t.co/CVQdQVJpQ7
City of Hope cancer researchers demonstrated promising clinical activity in CAR T-cell therapy for certain #braincancers and #prostatecancers in two new groundbreaking studies. Read the studies here: https://t.co/ebAvecDQxK @cityofhope
Natural killer cell infiltration in #ProstateCancers predicts improved patient outcomes. Nicholas Zorko, MD, PhD @UMNews joins @AndreaMiyahira @PCFnews to discuss the promising role of NK cells described in his team's work published in @pcan_journal > https://t.co/CVQdQVJpQ7
Natural killer cell infiltration in #ProstateCancers predicts improved patient outcomes. Nicholas Zorko, MD, PhD @UMNews joins @AndreaMiyahira @PCFnews to discuss the promising role of NK cells described in his team's work published in @pcan_journal > https://t.co/CVQdQVJpQ7
Natural killer cell infiltration in #ProstateCancers predicts improved patient outcomes. Nicholas Zorko, MD, PhD @UMNews joins @AndreaMiyahira @PCFnews to discuss the promising role of NK cells described in his team's work published in @pcan_journal > https://t.co/CVQdQVJpQ7
A new screening protocol can detect aggressive #prostateCancers more selectively @JAMA_current https://t.co/HCrehTlNRT
SWI/SNF activity has therapeutic implications in Wnt-dependent #prostatecancers. We have untangle a new mechanism of vulnerability via the master transcriptional regulator TCF7L2. Led by Phillip Thienger with Bob Yauch @genentech. @DBMR_UniBe @PCFNews https://t.co/Zq66ZTLCvx
#ICYMI: BriaCell’s poster presentation at the #SITC23 annual meeting highlighted the development details & activities of BriaCell’s next generation off-the-shelf personalized #immunotherapies for breast & #prostatecancers. Find it here: https://t.co/LaafsVPUOY $BCTX $BCTXW
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
241.6M followers
Barack Obama
@barackobama
119M followers
Cristiano Ronaldo
@cristiano
114.2M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
89.9M followers
Taylor Swift
@taylorswift13
83.8M followers
Lady Gaga
@ladygaga
75.3M followers
Virat Kohli
@imvkohli
73.1M followers
Kim Kardashian
@kimkardashian
70.8M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.2M followers
Bill Gates
@billgates
65M followers
Selena Gomez
@selenagomez
62.9M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers